ARTV - Latest News
Artiva Biotherapeutics, Inc. (ARTV), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $542.2M. Beta to the broader market is 2.18.
The article list below shows the most recent ARTV headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ARTV Headlines
2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC
defenseworld.net - Aug 26, 2026
5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) in the second quarter, according to the comp
Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR)
defenseworld.net - Aug 11, 2026
ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companie
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com - Aug 6, 2026
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - Jul 17, 2026
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
zacks.com - Jul 8, 2026
Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc.
How News Affects ARTV Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ARTV's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ARTV news questions
- What is the latest ARTV news headline?
- The most recent ARTV headline (Aug 26, 2026) is "2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ARTV news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ARTV news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ARTV options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.